New Posters

Fibrosis regression after Tirzepatide treatment of Non- cirrhotic MASH for 52 weeks occurred in a zone-dependent manner

Comparative evaluation of zonal fibrosis patterns in pediatric and adult metabolic dysfunction-associated steatohepatitis biopsies using Second Harmonic Generation/Two Photon Excitation-based qFibrosis analysis

Efruxifermin significantly reduced proportion of subjects with at-risk MASH and led to near-complete histological disease reversal at week 96 in the HARMONY study

AI and digital-based pathology corroborate reduction in fibrosis observed by conventional pathology with efruxifermin treatment of patients with F2-F3 MASH in the HARMONY study

Evaluating impact of weight changes on histological patterns of liver fibrosis in MASH: implications for spatial interrogation

Validating pre-identified morphological baseline features for predicting fibrosis progression in MAESTRO-NASH

Stain-free digital pathology imaging provides microarchitecturally-resolved insights into scar evolution and histological injury allowing direct clinical outcome prediction in metabolic dysfunction-associated steatotic liver disease

Evaluation of the consistency and heterogeneity of fibrosis assessment in adjacent virtual liver needle biopsies using AI- based qFibrosis

Independent validation of Second Harmonic Generation/Two- photon excitation imaging and artificial intelligence-based SNOF index for metabolic dysfunction associated steatohepatitis cirrhosis assessment

Application of artificial intelligence algorithm as a vascular evaluation tool for intra-stage assessment in the cirrhotic patients with metabolic dysfunction-associated steatotic liver disease